11/03/14: Associate Editor Posts

Halliburton, Fraud-On-The-Market Presumption Established; What Now?

By Vanessa Wong

In the much awaited securities fraud litigation case Halliburton Co. v. Erica P. John Fund, Inc., the Supreme Court upheld the presumption of reliance standard from Basic v Levinson. To recover damages in a private securities fraud action, investors must prove that they relied on the defendant’s material misstatement or omission in connection with the purchase or sale of a security. Basic held that investors could satisfy the reliance requirement by invoking a rebuttable presumption of reliance, instead of having to prove direct reliance on a misrepresentation, based on the so-called “fraud-on-the-market” theory. The theory posits that, in an efficient market, securities’ prices reflect all publicly available information, including any material misrepresentations. Thus, when an investor buys or sells a stock in the market, he does so “in reliance on the integrity of that price.”

Halliburton, however, is a bittersweet victory for plaintiffs. In that case, the Supreme Court also held that defendants may now attempt to rebut the Basic presumption earlier—at the class certification stage—with evidence of a lack of price impact. Any further obstacles in the way of securities-fraud plaintiffs would not only be harmful to plaintiffs but also be a misdirected stab toward the bigger problem, corporate fraud. Attention should now be paid to corporate fraud and not to the relatively insignificant frivolous suits here and there.

 

The Fix is in; Commandeering New Jersey Gambling Rights

By Sal Alfieri

New Jersey is known for many things, including unique breakfast meat from the famous Jersey Shore and the land of little Las Vegas, Atlantic City. Atlantic City and gambling attributed to the area have been a major source of income since the first legal casino was approved in 1978. In the past decade, however, Atlantic City casinos have been the victim of a consistent decrease in revenue produced from gambling. In the past year, Atlantic City casinos have dwindled from 12 operating casinos to just 8, most notably the closing of the 2.4 billion dollar failed experiment, Revel Hotel and Casino. Coupled with the closing of casinos is the inevitable job loss for thousands of workers employed in Atlantic City. It is estimated that some 8,000 workers will or have lost their jobs since the struggles to produce income forced closure of a third of New Jersey’s operating casinos. To stick the knife even deeper, neighboring states of Maryland and Pennsylvania have begun to construct casinos of their own, which will be in direct competition to the remaining casinos in Atlantic City.

In an attempt to combat the declining revenue produced from gambling, New Jersey has made national headlines with the proposed introduction of sports gambling. However, the introduction of sports betting is not cut and dry; rather, New Jersey has some major challenges ahead. The Professional and Amateur Sports Protection Act (“PASPA”) passed in 1992 prevents a state, other than the four “grandfathered” under PASPA, from promoting, authorizing or licensing sports betting. New Jersey, along with a few other states, has begun to explore the ability to both bypass PASPA and allow sports betting by challenging the constitutionality of the Act. The most compelling of these constitutional challenges against PASPA is the Tenth Amendment Anti-Commandeering challenge. Since the construction of the U.S. Constitution, states have held their individual sovereignty. With this sovereignty comes the power to control the outlets chosen to produce internal revenue. The issue has now become whether the enactment of PASPA violates New Jersey’s constitutionally protected right of state sovereignty, bringing into question the fundamental principles of Federalism. Regardless of the outcome, New Jersey’s case against PASPA will reinvigorate ideas of Federalism and in the end will leave a clear picture of how, in this day and age, the Tenth Amendment operates to protect a state’s individual rights.

 

Minimally Manipulated (according to the FDA)

By Caroline Stewart

In February of this year in United States v. Regenerative Sciences, LLC, the DC Circuit affirmed the FDA’s jurisdiction to regulate development and commercialization of a patient’s adult own stem cells as a new drug or biological product, subject to “human cell, tissue and tissue-based products” (HCT/Ps) regulations.  This means that even private medical practices must conduct clinical trials and obtain approval before marketing, comply with current good manufacturing practices, and meet specific labeling requirements for these “drugs,” even when they are used to treat the patients from which the cells came. With respect to this particular case, the FDA likely harbored a fear that culturing the patients’ cells could cause them to become carcinogenic, but one of the rationales for categorizing the patients’ own (autologous) cells as drugs was the degree of manipulation required to create the therapy.

There are two other recent FDA actions that further call into question the FDA’s broad authority to exercise control over a wide range of HCT/P products. For instance, in August 2013, MiMedx received an “Untitled Letter” from the FDA that stated that the company’s micronized allografts (amniotic/chorionic tissue for transplant to other patients) do not meet the HCT/P requirements because they are more than “minimally manipulated.” These micronized allografts have been commercially available for years and have previously withstood FDA scrutiny. In another example, in September 2013, OvaScience also received an “Untitled Letter” advising the company to file an Investigational New Drug Application (IND) for their AUGMENT treatment. AUGMENT is not a drug, but rather a process by which a woman’s eggs are injected with mitochondria from her own egg precursor cells during in vitro fertilization (IVF) in order to potentially improve the success of IVF.

The current HCT/P framework is too restrictive and should be re-designed. In particular, regulations should be tailored for the subcategories of products or therapies. Otherwise, the FDA may be viewed as overstepping its boundaries by interfering with doctors’ practice of medicine, a state function, such as with Regenerative Sciences or OvaScience, or FDA may also be viewed as acting arbitrarily with respect to enforcing its own regulations, as with MiMedx.

 

Where Have All The Innovators Gone: A Critique of the United States’ Biologics Price Competition and Innovation Act

By Joyce Lee

The life sciences industry is poised for growth, and amongst its biggest drivers are an aging population, increasing prevalence of chronic diseases, greater access to medications worldwide, technological advancements and product innovation, and impending healthcare reform that would increase government funding and insurance coverage.

And perhaps of the most exciting areas of life sciences today, the biosimilar market may also be one of the most lucrative. In a September 29, 2014 Thomson Reuters BioWorld report, analysts estimate that, by 2020, biosimilars will account for about $25 billion out of $100 billion in sales for off-patent biologics. With 245 biopharma companies in markets throughout the world and 700 follow-on biologics therapies in the pipelines (many already approved), the investor world is going abuzz with biosimilar talk. Nonetheless, despite all the activity, Sandoz was the first company to file for biosimilar approval in US on July 24, 2014, and if approved, it could be the first biosimilar to market in the US. This is in stark contrast with the European Union, who would have nineteen, and Japan, who would have six.

The United States developed a regulatory pathway for the approval of biosimilar products, the Biologics Price Competition and Innovation Act (BPCIA) of Title VII of the Patient Protection and Affordable Care Act. The BPCIA amends the Public Health Service Act (PHSA) to allow biosimilar manufacturers an abbreviated approval process for their products under section 351(k). While the US Food and Drug Administration (FDA) released three draft guidance documents related to implementation of the BPCIA, the BPCIA remains criticized for its lack of clarity, thus causing companies to proceed with trepidation into the US market.

I would like to compare and contrast the US’s regulatory approach to that of the European Union’s European Medicines Agency (EMEA) and the pharmerging markets of China, India and Brazil. I would also like to explore the countries’ guidance regarding clinical trial pathways, safety and efficacy measures, comparative assessments between the reference product and the proposed product (e.g. pharmacokinetic, pharmacodynamic, and immunogenicity studies), substitutability and interchangeability issues, and the use of foreign comparative data. With all these considerations in mind, I would like to discuss whether the abbreviated pathway for approval under the BPCIA sufficiently fosters the entry of biosimilar products into the US market as compared to the rest of the world.

 

Increased Involvement of the Children in Child Welfare Cases

By Pavitra Badami

Advocates and professionals involved in the arena of child welfare have been expressing the need for increased inclusion of youth and children in the child hearings. As a result, states such as New Jersey have devised different plans and benchmarks for the mandatory attendance of a minor during court hearings. I seek to advise the legislature of New Jersey to statutorily enable children to attend every court hearing concerning their future placement and displacement from their homes. Currently, the state of NJ requires that a minor be given notice to attend his own permanency hearing, once a year. However, attending one hearing a year does not increase the participation of minors nor does it assure them an opportunity to always be heard by the courts regarding abuse and neglect matters.

There are few measures that can meaningfully evaluate the role of a minor’s involvement in abuse and neglect court proceedings but sufficient evidence exists to support the assertion that in New Jersey, children play a passive role in expressing their goals and needs to the professionals and the legal system that determines their present and future opportunities. However, New Jersey statutes and court decisions strongly set the foundation for increased involvement of children specifically in child abuse and neglect matters. Currently, as per 11 N.J.S.A. 30:4C-61.2.b, a child is entitled to attend a permanency hearing that will determine the plan the Division of Child Protection and Permanency (the State) has devised for the child. The statute leaves the presence of the child up to the discretion of the deciding Judge and the circumstances presented by the Division and the other litigating parties.

I seek to examine the different statutes and laws governing youth participation in different states across the nation for child welfare court proceedings. Particularly, I will discuss factors contributing to and affecting youth participation in child welfare cases in New Jersey and will use New Jersey statutes and court decisions as the framework to explain current low rates of youth participation. I would further advise the New Jersey Legislature to provide a strong statutory basis for adopting laws that allow for routine youth participation and use child welfare laws in states such as California, New York, and Delaware to increase the participation of children in court, specifically in child abuse and neglect cases. Lastly, I will examine the benefits and limitations of increased youth participation in court proceedings and its feasibility given the restraints on the legal system’s resources.






Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • del.icio.us
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
Share